

\*\* Mean hourly wage for Medical Secretaries (43–6013).

\*\*\* Mean hourly wage for Pharmacy Technicians (29–2052).

Occupational Employment Statistics, May 2017 National Occupational Employment and Wage Estimates United States, U.S. Department of Labor, Bureau of Labor Statistics.

### Request for Comments

In accordance with the Paperwork Reduction Act, comments on AHRQ's information collection are requested with regard to any of the following: (a) Whether the proposed collection of information is necessary for the proper performance of AHRQ's health care research and health care information dissemination functions, including whether the information will have practical utility; (b) the accuracy of AHRQ's estimate of burden (including hours and costs) of the proposed collection(s) of information; (c) ways to enhance the quality, utility and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information upon the respondents, including the use of automated collection techniques or other forms of information technology.

Comments submitted in response to this notice will be summarized and included in the Agency's subsequent request for OMB approval of the proposed information collection. All comments will become a matter of public record.

Gopal Khanna,

Director.

[FR Doc. 2019–08765 Filed 4–30–19; 8:45 am]

BILLING CODE 4160–90–P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. FDA–2013–N–0134]

#### Agency Information Collection Activities; Proposed Collection; Comment Request; Mammography Quality Standards Act Requirements

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the **Federal Register** concerning each

proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the estimated reporting, recordkeeping, and third-party disclosure burden associated with the Mammography Quality Standards Act requirements.

**DATES:** Submit either electronic or written comments on the collection of information by July 1, 2019.

**ADDRESSES:** You may submit comments as follows. Please note that late, untimely filed comments will not be considered. Electronic comments must be submitted on or before July 1, 2019. The <https://www.regulations.gov> electronic filing system will accept comments until 11:59 p.m. Eastern Time at the end of July 1, 2019. Comments received by mail/hand delivery/courier (for written/paper submissions) will be considered timely if they are postmarked or the delivery service acceptance receipt is on or before that date.

#### Electronic Submissions

Submit electronic comments in the following way:

- **Federal eRulemaking Portal:** <https://www.regulations.gov>. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to <https://www.regulations.gov> will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else's Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on <https://www.regulations.gov>.

- If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see “Written/Paper Submissions” and “Instructions”).

#### Written/Paper Submissions

Submit written/paper submissions as follows:

- **Mail/Hand Delivery/Courier (for written/paper submissions):** Dockets Management Staff (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.

- For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in “Instructions.”

**Instructions:** All submissions received must include the Docket No. FDA–2013–N–0134 for “Agency Information Collection Activities; Proposed Collection; Comment Request; Mammography Quality Standards Act Requirements.” Received comments, those filed in a timely manner (see **ADDRESSES**), will be placed in the docket and, except for those submitted as “Confidential Submissions,” publicly viewable at <https://www.regulations.gov> or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday.

- **Confidential Submissions—**To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states “THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.” The Agency will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on <https://www.regulations.gov>. Submit both copies to the Dockets Management Staff. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as “confidential.” Any information marked as “confidential” will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA's posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: <https://www.gpo.gov/fdsys/pkg/FR-2015-09-18/pdf/2015-23389.pdf>.

**Docket:** For access to the docket to read background documents or the

electronic and written/paper comments received, go to <https://www.regulations.gov> and insert the docket number, found in brackets in the heading of this document, into the "Search" box and follow the prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.

**FOR FURTHER INFORMATION CONTACT:** Amber Sanford, Office of Operations, Food and Drug Administration, Three White Flint North, 10A-12M, 11601 Landsdown St., North Bethesda, MD 20852, 301-796-8867, [PRAStaff@fda.hhs.gov](mailto:PRAStaff@fda.hhs.gov).

**SUPPLEMENTARY INFORMATION:** Under the PRA (44 U.S.C. 3501-3520), Federal Agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. "Collection of information" is defined in 44 U.S.C. 3502(3) and 5 CFR 1320.3(c) and includes Agency requests or requirements that members of the public submit reports, keep records, or provide information to a third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A)) requires Federal Agencies to provide a 60-day notice in the **Federal Register** concerning each proposed collection of information, including each proposed extension of an existing collection of information, before submitting the collection to OMB for approval. To comply with this requirement, FDA is publishing notice of the proposed collection of information set forth in this document.

With respect to the following collection of information, FDA invites

comments on these topics: (1) Whether the proposed collection of information is necessary for the proper performance of FDA's functions, including whether the information will have practical utility; (2) the accuracy of FDA's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques, when appropriate, and other forms of information technology.

### Mammography Quality Standards Act Requirements—21 CFR Part 900

*OMB Control Number 0910-0309—Extension*

The Mammography Quality Standards Act (Pub. L. 102-539) requires the establishment of a Federal certification and inspection program for mammography facilities; regulations and standards for accreditation and certification bodies for mammography facilities; and standards for mammography equipment, personnel, and practices, including quality assurance. The intent of these regulations is to assure safe, reliable, and accurate mammography on a nationwide level. Under the regulations, as a first step in becoming certified, mammography facilities must become accredited by an FDA-approved accreditation body (AB). This requires undergoing a review of their clinical

images and providing the AB with information showing that they meet the equipment, personnel, quality assurance, and quality control standards, and have a medical reporting and recordkeeping program, a medical outcomes audit program, and a consumer complaint mechanism. On the basis of this accreditation, facilities are then certified by FDA or an FDA-approved State certification agency and must prominently display their certificate. These actions are taken to ensure safe, accurate, and reliable mammography on a nationwide basis.

The following sections of Title 21 of the Code of Federal Regulations (CFR) are not included in the burden tables because they are considered usual and customary practice and were part of the standard of care prior to the implementation of the regulations, therefore, they resulted in no additional burden: 21 CFR 900.12(c)(1) and (3) and 900.3(f)(1). 21 CFR 900.24(c) was also not included in the burden tables because if a certifying State had its approval withdrawn, FDA would take over certifying authority for the affected facilities. Because FDA already has all the certifying State's electronic records, there wouldn't be an additional reporting burden.

We have rounded numbers in the "Total Hours" column in all three burden tables. (Where the number was a portion of 1 hour, it has been rounded to 1 hour. All other "Total Hours" have been rounded to the nearest whole number.)

FDA estimates the burden of this collection of information as follows:

TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN

Activity/21 CFR section/FDA Form No.	Number of respondents	Number of responses per respondent	Total annual responses	Average burden per response	Total hours <sup>1</sup>	Total capital costs	Total operating and maintenance costs
Notification of intent to become an AB—900.3(b)(1).	0.33	1	0.33	1 .....	1		
Application for approval as an AB; full <sup>2</sup> —900.3(b)(3).	0.33	1	0.33	320 .....	106	\$10,776	
Application for approval as an AB; limited <sup>3</sup> —900.3(b)(3).	5	1	5	30 .....	150		
AB renewal of approval—900.3(c) .....	1	1	1	15 .....	15		
AB application deficiencies—900.3(d)(2) .....	0.1	1	0.1	30 .....	3		
AB resubmission of denied applications—900.3(d)(5).	0.1	1	0.1	30 .....	3		
Letter of intent to relinquish accreditation authority—900.3(e).	0.1	1	0.1	1 .....	1		
Summary report describing all facility assessments—900.4(f).	330	1	330	7 .....	2,310		\$83,618
AB reporting to FDA; facility <sup>4</sup> —900.4(h) .....	8,654	1	8,654	1 .....	8,654		4,663
AB reporting to FDA; AB <sup>5</sup> —900.4(h) .....	5	1	5	10 .....	50		
AB financial records—900.4(i)(2) .....	1	1	1	16 .....	16		
Former AB new application—900.6(c)(1) .....	0.1	1	0.1	60 .....	6		
Reconsideration of accreditation following appeal—900.15(d)(3)(ii).	1	1	1	2 .....	2		
Application for alternative standard—900.18(c).	2	1	2	2 .....	4		
Alternative standard amendment—900.18(e)	10	1	10	1 .....	10		
Certification agency application—900.21(b)	0.33	1	0.33	320 .....	106	32,327	224

TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN—Continued

Activity/21 CFR section/FDA Form No.	Number of respondents	Number of responses per respondent	Total annual responses	Average burden per response	Total hours <sup>1</sup>	Total capital costs	Total operating and maintenance costs
Certification agency application deficiencies—900.21(c)(2).	0.1	1	0.1	30 .....	3		
Certification electronic data transmission—900.22(h).	5	200	1000	0.083 (5 minutes) .....	83		
Changes to standards—900.22(i) .....	2	1	2	30 .....	60		22
Certification agency minor deficiencies—900.24(b).	1	1	1	30 .....	30		
Appeal of adverse action taken by FDA—900.25(a).	0.2	1	0.2	16 .....	3		
Inspection fee exemption—Form FDA 3422	700	1	700	0.25 (15 minutes) .....	175		
Total .....					11,791	43,103	88,527

<sup>1</sup> Total hours have been rounded.<sup>2</sup> One-time burden.<sup>3</sup> Refers to accreditation bodies applying to accredit specific full-field digital mammography units.<sup>4</sup> Refers to the facility component of the burden for this requirement.<sup>5</sup> Refers to the AB component of the burden for this requirement.

TABLE 2—ESTIMATED ANNUAL RECORDKEEPING BURDEN

Activity/21 CFR section	Number of record-keepers	Number of records per recordkeeper	Total annual records	Average burden per recordkeeping	Total hours <sup>1</sup>	Total capital costs	Total operating and maintenance costs
AB transfer of facility records—900.3(f)(1) ...	0.1	1	0.1	0 .....	1		
Consumer complaints system; AB—900.4(g)	5	1	5	1 .....	5		
Documentation of interpreting physician initial requirements—900.12(a)(1)(i)(B)(2).	87	1	87	8 .....	696		
Documentation of interpreting physician personnel requirements—900.12(a)(4).	8,654	4	34,616	1 .....	34,616		
Permanent medical record—900.12(c)(4) .....	8,654	1	8,654	1 .....	8,654	\$30,171	
Procedures for cleaning equipment—900.12(e)(13).	8,654	52	450,008	0.083 (5 minutes) .....	37,351		
Audit program—900.12(f) .....	8,654	1	8,654	16 .....	138,464		
Consumer complaints system; facility—900.12(h)(2).	8,654	2	17,308	1 .....	17,308		
Certification agency conflict of interest—900.22(a).	5	1	5	1 .....	5		
Processes for suspension and revocation of certificates—900.22(d).	5	1	5	1 .....	5		
Processes for appeals—900.22(e) .....	5	1	5	1 .....	5		
Processes for additional mammography review—900.22(f).	5	1	5	1 .....	5		
Processes for patient notifications—900.22(g).	3	1	3	1 .....	3		\$32
Evaluation of certification agency—900.23 ...	5	1	5	20 .....	100		
Appeals—900.25(b) .....	5	1	5	1 .....	5		
Total .....					237,223	30,171	32

<sup>1</sup> Total hours have been rounded.TABLE 3—ESTIMATED ANNUAL THIRD-PARTY DISCLOSURE BURDEN <sup>1</sup>

Activity/21 CFR section	Number of respondents	Number of disclosures per respondent	Total annual disclosures	Average burden per disclosure	Total hours <sup>2</sup>	Total operating and maintenance costs
Notification of facilities that AB relinquishes its accreditation—900.3(f)(2).	0.1	1	0.1	200 .....	20	\$54
Clinical images; facility <sup>3</sup> —900.4(c), 900.11(b)(1), and 900.11(b)(2).	2,885	1	2,885	1.44 .....	4,154	248,670
Clinical images; AB <sup>4</sup> —900.4(c) .....	5	1	5	416 .....	2,080	
Phantom images; facility <sup>3</sup> —900.4(d), 900.11(b)(1), and 900.11(b)(2).	2,885	1	2,885	0.72 (43 minutes) ....	2,077	
Phantom images; AB <sup>4</sup> —900.4(d) ..	5	1	5	208 .....	1,040	
Annual equipment evaluation and survey; facility <sup>3</sup> —900.4(e), 900.11(b)(1), and 900.11(b)(2).	8,654	1	8,654	1 .....	8,654	9,325
Annual equipment evaluation and survey; AB <sup>4</sup> —900.4(e).	5	1	5	1,730 .....	8,650	

TABLE 3—ESTIMATED ANNUAL THIRD-PARTY DISCLOSURE BURDEN<sup>1</sup>—Continued

Activity/21 CFR section	Number of respondents	Number of disclosures per respondent	Total annual disclosures	Average burden per disclosure	Total hours <sup>2</sup>	Total operating and maintenance costs
Provisional mammography facility certificate extension application—900.11(b)(3).	0	1	0	0.5 (30 minutes) .....	1	
Mammography facility certificate reinstatement application—900.11(c).	312	1	312	5 .....	1,560	
Lay summary of examination—900.12(c)(2).	8,654	5,085	44,055,590	0.083 (5 minutes) ....	3,652,464	25,861,265
Lay summary of examination; patient refusal <sup>5</sup> —900.12(c)(2).	87	1	87	0.5 (30 minutes) .....	44	
Report of unresolved serious complaints—900.12(h)(4).	20	1	20	1 .....	20	
Information regarding compromised quality; facility <sup>3</sup> —900.12(j)(1).	20	1	20	200 .....	4,000	324
Information regarding compromised quality; AB <sup>4</sup> —900.12(j)(1).	20	1	20	320 .....	6,400	646
Patient notification of serious risk—900.12(j)(2).	5	1	5	100 .....	500	20,878
Reconsideration of accreditation—900.15(c).	5	1	5	2 .....	10	
Notification of requirement to correct major deficiencies—900.24(a).	0.4	1	0.4	200 .....	80	73
Notification of loss of approval; major deficiencies—900.24(a)(2).	0.15	1	0.15	100 .....	15	27
Notification of probationary status—900.24(b)(1).	0.3	1	0.3	200 .....	60	55
Notification of loss of approval; minor deficiencies—900.24(b)(3).	0.15	1	0.15	100 .....	15	27
Total .....					3,691,842	26,141,344

<sup>1</sup> There are no capital costs associated with the collection of information.

<sup>2</sup> Total hours have been rounded.

<sup>3</sup> Refers to the facility component of the burden for this requirement.

<sup>4</sup> Refers to the AB component of the burden for this requirement.

<sup>5</sup> Refers to the situation where a patient specifically does not want to receive the lay summary of her exam.

FDA has adjusted the number of respondents for § 900.3(c) “AB renewal of approval” to one. This adjustment resulted in a 14-hour increase to the hour-burden estimate. Additionally, we updated the capital costs and operating and maintenance costs by adjusting them for inflation since the last update to those estimates. This adjustment resulted in a \$1,893,071 increase to the estimated capital and operating and maintenance costs (\$24,410,106 previously; \$26,303,177 current extension request).

Dated: April 24, 2019.

**Lowell J. Schiller,**

*Principal Associate Commissioner for Policy.*

[FR Doc. 2019-08784 Filed 4-30-19; 8:45 am]

**BILLING CODE 4164-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. FDA-2012-N-0559]

#### Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Public Health Service Guideline on Infectious Disease Issues in Xenotransplantation

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.

**DATES:** Fax written comments on the collection of information by May 31, 2019.

**ADDRESSES:** To ensure that comments on the information collection are received, OMB recommends that written comments be faxed to the Office of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer, Fax: 202-395-7285, or emailed to [oir\\_submission@omb.eop.gov](mailto:oir_submission@omb.eop.gov). All comments should be identified with the OMB control number 0910-0456. Also include the FDA docket number found in brackets in the heading of this document.

**FOR FURTHER INFORMATION CONTACT:** JonnaLynn Capezzuto, Office of Operations, Food and Drug Administration, Three White Flint North, 10A-12M, 11601 Landsdown St., North Bethesda, MD 20852, 301-796-3794, [PRStaff@fda.hhs.gov](mailto:PRStaff@fda.hhs.gov).

**SUPPLEMENTARY INFORMATION:** In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance.